Cargando…
Initial Findings on the Use of [(225)Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors
OBJECTIVES: This study aimed to evaluate the stability, safety, and efficacy of alpha-targeted therapy with [(225)Ac]Ac-DOTATATE in patients with grade 1/2 metastatic neuroendocrine tumors (NETs). METHODS: This retrospective cohort included patients (n=11) with metastatic NETs from different primary...
Autores principales: | Demirci, Emre, Alan Selçuk, Nalan, Beydağı, Gamze, Ocak, Meltem, Toklu, Türkay, Akçay, Kaan, Kabasakal, Levent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600558/ https://www.ncbi.nlm.nih.gov/pubmed/37870290 http://dx.doi.org/10.4274/mirt.galenos.2023.38258 |
Ejemplares similares
-
Almost Complete Response with a Single Administration (225)Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary
por: Alan Selçuk, Nalan, et al.
Publicado: (2022) -
Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry
por: Kabasakal, Levent, et al.
Publicado: (2017) -
Successful Combination of Olaparib and (225)Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
por: Kröcher, Anke, et al.
Publicado: (2023) -
[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022) -
Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study
por: Yadav, Madhav Prasad, et al.
Publicado: (2021)